Molecular Partners’ total offer size of IPO reaches CHF 106.2 million after partial exercise of IPO over-allotment option
Zurich-Schlieren, December 5, 2014. Molecular Partners AG announces that the total offer size of the initial public offering (“IPO”) amounts to CHF 106.2 million, of which gross proceeds from the primary shares issued are CHF 104.1 million. The Joint Bookrunners of Molecular Partners’ IPO have partially exercised the over-allotment option yesterday at the offer price of CHF 22.40 per share.
Including the exercise of the over-allotment option of 340,140 new registered shares, the IPO resulted in the issuance of a total of 4,740,140 shares, corresponding to 24.1% of the share capital. The aggregate number of shares in issue after the partial exercise of the over-allotment option is 19,640,140 registered shares with a nominal value of CHF 0.10 each. The free float therefore amounts to 24.3%.
J.P. Morgan acted as the Sole Global Coordinator and Joint Bookrunner and UBS Investment Bank acted as Joint Bookrunner. Cowen and Company and Bank am Bellevue acted as Co-Managers in connection with the IPO.
About Molecular Partners AG
Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new powerful http://www.mindanews.com/buy-accutane/ class of therapies known as DARPins™. DARPins™ are potent, specific and versatile small protein therapies which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to enable a “multibenefit” approach to treatment which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins™ have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. Its most advanced product candidate is abicipar pegol, for which the company’s partner Allergan plans to initiate a Phase III clinical trial in wet AMD in 2015. The company has ongoing research and development partnerships with leading pharmaceutical companies including Allergan, Roche and Janssen and is backed by established biotech investors.
For more information regarding Molecular Partners, please visit: www.molecularpartners.com.